title: Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model.
abstract: Murine studies have shown that immunological targeting of fibroblast activation protein (FAP) can elicit protective immunity in the absence of significant pathology. Fibroblast activation protein is a product overexpressed by tumor-associated fibroblasts (TAF) and is the predominant component of the stoma in most types of cancer. Tumor-associated fibroblasts differ from normal adult tissue fibroblasts, and instead resemble transient fetal and wound healing-associated fibroblasts. Tumor-associated fibroblasts are critical regulators of tumorigenesis, but differ from tumor cells by being more genetically stable. Therefore, in comparison to tumor cells, TAF may represent more viable therapeutic targets for cancer immunotherapy. To specifically target TAF, we constructed a DNA vaccine directed against FAP. This vaccine significantly suppressed primary tumor and pulmonary metastases primarily through CD8(+) T-cell-mediated killing in tumor-bearing mice. Most importantly, tumor-bearing mice vaccinated against FAP exhibited a 1.5-fold increase in lifespan and no significant pathology. These results suggest that FAP, a product preferentially expressed by TAF, could function as an effective tumor rejection antigen.
authors.affiliation: State Key Laboratory of Biotherapy, West China Hospital and School of Life Science, Sichuan University Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu, China.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Wen
authors.forename: Chun-Ting
authors.initials: CT
authors.lastname: Wang
authors.forename: Tian-Tai
authors.initials: TT
authors.lastname: Ma
authors.forename: Zhi-Yong
authors.initials: ZY
authors.lastname: Li
authors.forename: Li-Na
authors.initials: LN
authors.lastname: Zhou
authors.forename: Bo
authors.initials: B
authors.lastname: Mu
authors.forename: Fei
authors.initials: F
authors.lastname: Leng
authors.forename: Hua-Shan
authors.initials: HS
authors.lastname: Shi
authors.forename: Ya-Ou
authors.initials: YO
authors.lastname: Li
authors.forename: Yu-Quan
authors.initials: YQ
authors.lastname: Wei
mesh_terms: D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D004195:Disease Models, Animal; D010450:Endopeptidases; D005260:Female; D005347:Fibroblasts / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D018093:Gelatinases / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D007114:Immunization / Q000379:methods; D007150:Immunohistochemistry; D007167:Immunotherapy / Q000379:methods*; D008175:Lung Neoplasms / Q000276:immunology / Q000517:prevention & control / Q000556:secondary; D008565:Membrane Proteins / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D012697:Serine Endopeptidases / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D016019:Survival Analysis; D047368:Tumor Burden / Q000276:immunology; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology*; D000099167:Fibroblast Activation Protein Alpha
chemical_list: D019496:Cancer Vaccines; D010450:Endopeptidases; D018093:Gelatinases; D008565:Membrane Proteins; D012697:Serine Endopeptidases; D019444:Vaccines, DNA; D000099167:Fibroblast Activation Protein Alpha
references.citation: Onkologie. 2003 Feb;26(1):44-8
references.pmid: 12624517
references.citation: J Exp Med. 2003 Nov 17;198(10):1487-93
references.pmid: 14623905
references.citation: Proc Natl Acad Sci U S A. 1990 Sep;87(18):7235-9
references.pmid: 2402505
references.citation: J Cell Physiol. 2002 Sep;192(3):259-67
references.pmid: 12124771
references.citation: Br J Clin Pharmacol. 2001 Feb;51(2):177-80
references.pmid: 11259992
references.citation: Adv Immunol. 2000;74:181-273
references.pmid: 10605607
references.citation: Oncogene. 1997 Feb 27;14(8):977-85
references.pmid: 9050997
references.citation: Clin Cancer Res. 2005 Aug 1;11(15):5566-71
references.pmid: 16061874
references.citation: Semin Cancer Biol. 2002 Apr;12(2):97-104
references.pmid: 12027581
references.citation: Nat Med. 2000 Oct;6(10):1160-6
references.pmid: 11017149
references.citation: Cancer Res. 2002 Aug 15;62(16):4767-72
references.pmid: 12183436
references.citation: Nature. 2001 May 17;411(6835):375-9
references.pmid: 11357145
references.citation: Nat Biotechnol. 1997 Jul;15(7):647-52
references.pmid: 9219267
references.citation: Cancer Res. 1999 Nov 1;59(21):5412-6
references.pmid: 10554007
references.citation: J Exp Med. 1992 Jan 1;175(1):139-46
references.pmid: 1309851
references.citation: Cancer Res. 1993 Jul 15;53(14):3327-35
references.pmid: 8391923
references.citation: Science. 2002 May 10;296(5570):1046-9
references.pmid: 12004111
references.citation: J Clin Invest. 2006 Jul;116(7):1955-62
references.pmid: 16794736
references.citation: Cancer Res. 2005 Dec 1;65(23):11156-63
references.pmid: 16322266
references.citation: Blood. 2003 Sep 1;102(5):1815-23
references.pmid: 12750177
references.citation: Science. 2004 Feb 6;303(5659):848-51
references.pmid: 14764882
references.citation: J Clin Invest. 2002 Jun;109(12):1551-9
references.pmid: 12070302
references.citation: J Leukoc Biol. 1998 Sep;64(3):275-90
references.pmid: 9738653
references.citation: J Biol Chem. 1999 Dec 17;274(51):36505-12
references.pmid: 10593948
references.citation: Mol Cell Biol. 2000 Feb;20(3):1089-94
references.pmid: 10629066
references.citation: Cancer Res. 1998 Feb 15;58(4):737-42
references.pmid: 9485029
references.citation: J Exp Med. 2001 Dec 3;194(11):1549-59
references.pmid: 11733570
references.citation: Cancer Res. 1996 Mar 1;56(5):1104-10
references.pmid: 8640768
references.citation: Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1553-8
references.pmid: 9990062
references.citation: Biochim Biophys Acta. 1997 Jul 10;1361(1):11-9
references.pmid: 9247085
references.citation: Mol Cancer Ther. 2005 Mar;4(3):351-60
references.pmid: 15767544
references.citation: Nat Med. 1996 Oct;2(10):1096-103
references.pmid: 8837607
references.citation: Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6779-87
references.pmid: 18006780
references.citation: Clin Cancer Res. 2007 Mar 15;13(6):1736-41
references.pmid: 17363526
references.citation: Cancer Cell. 2003 Jan;3(1):17-22
references.pmid: 12559172
references.citation: Int J Cancer. 1997 May 2;71(3):383-9
references.pmid: 9139873
references.citation: Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5657-61
references.pmid: 7911242
references.citation: Am J Pathol. 2000 Feb;156(2):393-8
references.pmid: 10666367
references.citation: Clin Cancer Res. 2003 May;9(5):1639-47
references.pmid: 12738716